OLMAOlema Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$178M
- 26% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$71M | −$107M | −$105M | −$142M | −$179M | 26% |
| Net income | −$71M | −$105M | −$97M | −$129M | −$162M | 25% |
| Operating cash flow | −$51M | −$82M | −$84M | −$104M | −$147M | 41% |
| Capex | $2M | $363K | — | $159K | — | |
| Stock-based comp | $16M | $19M | $17M | $23M | $18M | 22% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $25M | 1020 | — |
| FY2024 | $8M | −$5M | 238 | — |
| FY2023 | $3M | $22M | 573 | — |